PENETREX
LOE ApproachingNDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PENETREX is an oral small-molecule tablet approved in 1991 by Sanofi. The specific indication, mechanism of action, and pharmacologic class are not publicly detailed in available data. This product represents a legacy therapeutic with potential historical significance in its therapeutic area.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely in transition or consolidation mode, suggesting smaller team sizes and focus on retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PENETREX offers limited growth opportunity given its LOE-approaching lifecycle and zero linked job openings. This role is best suited for professionals seeking stability in a mature product or gaining experience in transition management and LOE strategy.
Brand ManagerCommercial Analyst
Worked on PENETREX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.